Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avadel AVDL -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (202)	9/25/2007 12:13:40 AM
From: Robohogs	Respond to of 240

From Rodman: GlaxoSmithKline’s Coreg CR increased 8% and 10% in new and total prescription volume, respectively, despite the introduction of generic Coreg. Total Coreg CR prescriptions are now at their highest levels to date, with 42,873 prescriptions recorded. Coreg CR’s share of prescriptions written for the Coreg franchise increased to 30% and 22% of new and total prescriptions, from 20% and 14% the previous week. This is due to the launch of generic immediate release Coreg. Coreg prescriptions declined 37% and 38% in new and total prescriptions, respectively. My add: The 42,873 is up 5% week over week but only up 1% vs. "normal" week 2 weeks ago. New Rx's lagging and are off from recent highs just over 20K. Jon